Compare Crispr Therapeutics AG (CRSP) vs Equinix Inc (EQIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Equinix Inc — how do they compare? Crispr Therapeutics AG trades at $53.87 (market cap $5.23B), while Equinix Inc trades at $1,067.9 (market cap $101.87B). The key difference: Equinix Inc is far larger — about 19.5× Crispr Therapeutics AG's market cap, and Equinix Inc pays a 2% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | EQIX | |
|---|---|---|
Market Cap | $5.23B | $101.87B |
Sector | Health | Real Estate |
52-Week High | $76.78 | $1.12K |
52-Week Low | $44.34 | $726.09 |
Enterprise Value | $3.65B | $123.00B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Equinix (EQIX) trades at $1,049.99, up 0.63% today, with a neutral technical signal as it hovers near resistance at $1,050. The stock shows strong analyst support (74.51% buy ratings) and a consensus price target of $1,120, driven by robust revenue growth, expanding net income margins to 15.63% in 2025, and positive news on AI infrastructure demand. However, high valuation ratios like a P/E of 66.44 and significant capital expenditures pose challenges.
The outlook remains positive due to sustained digital infrastructure demand and raised long-term guidance, but risks include elevated debt levels and earnings misses in recent quarters. Investors should weigh growth prospects against premium valuations and cash flow pressures from heavy investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
